{"id":"bopv-two-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"bOPV is a live attenuated vaccine containing weakened strains of poliovirus types 1 and 3. When administered orally, it replicates in the intestinal tract and triggers both mucosal and systemic immune responses, generating neutralizing antibodies and cellular immunity against these poliovirus serotypes. The two-dose regimen ensures adequate immunogenicity and protective antibody titers.","oneSentence":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:21.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1 and 3"}]},"trialDetails":[{"nctId":"NCT06137664","phase":"PHASE1, PHASE2","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","status":"RECRUITING","sponsor":"PATH","startDate":"2024-11-20","conditions":"Poliomyelitis","enrollment":2400},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT05166031","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine","status":"WITHDRAWN","sponsor":"Fidec Corporation","startDate":"2020-12","conditions":"Poliomyelitis","enrollment":""},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT02434770","phase":"PHASE3","title":"Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2015-08","conditions":"Poliomyelitis","enrollment":750},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT02412514","phase":"PHASE4","title":"Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":456},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01841671","phase":"PHASE4","title":"Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2013-04","conditions":"Polio","enrollment":570},{"nctId":"NCT01695798","phase":"PHASE4","title":"IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2012-10","conditions":"Immunity to Polio Vaccines in Malnourished Infants, Immunity to Polio Vaccines in Non-malnourished Infants","enrollment":840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"bOPV (two dose)","genericName":"bOPV (two dose)","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis. Used for Prevention of poliomyelitis caused by poliovirus types 1 and 3.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}